Identification of early symptoms and changes in QoL and functioning among men with primary localized prostate cancer who later develop metastases: A matched, prospective study
Open Access
- 10 February 2022
- journal article
- research article
- Published by Cambridge University Press (CUP) in Palliative and Supportive Care
- Vol. 21 (2) , 230-238
Abstract
Objective: To identify early symptoms and changes in QoL among men with primary localized prostate cancer (PC) who later develop metastases.Methods: From an ongoing prospective study of 3.885 men with localized PC, primarily treated with radiotherapy (RT), a subsample of men developing metastatic PC (mPC) following the first year after the start of RT and that had died during the follow-up (mPC group,n= 107) were matched against men who did not develop metastases (non-mPC group,n= 214). Data were collected using the EORTC QLQ-C30 and PCSS instruments. Non-parametric tests were performed for comparisons at baseline, end of RT, 3 months, and 1, 2, 3, and 5 years after RT.Results: The final sample consists of 317 men (mPCn= 106; non-mPCn= 211) who had completed at least one questionnaire. Initially, symptom levels were generally low and QoL and functioning high in both groups. An increasing difference between the groups was found, where the mPC group gradually deteriorated from the 2-year follow-up. Significant differences were found for several outcomes at 3 and 5 years. In a sensitivity analysis, where metastatic patients were removed from the time-point of verified metastases, most differences did not remain significant. Significant deterioration over time was seen within both groups for some outcomes.Significance of results: The results indicate that unmet supportive needs occur over time among these men. Worsening QoL or functioning and symptoms may be difficult to recognize when the development is gradual over several years, and with various access to systematic follow-up in late phases. This highlights the need for continuous monitoring of PC patients to detect needs for supportive interventions early and throughout the disease course, also among those with non-metastatic disease who have undergone curatively intended treatment.Keywords
Funding Information
- Familjen Kamprads Stiftelse (2150071)
This publication has 26 references indexed in Scilit:
- Metastatic castration-resistant prostate cancer. Part 2: helping patients make informed choices and managing treatment side effectsEuropean Journal of Oncology Nursing, 2013
- Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician’s attentionQuality of Life Research, 2013
- The Changing Natural History of Metastatic Prostate CancerThe Cancer Journal, 2013
- Palliative Care in Castrate-Resistant Prostate CancerUrologic Clinics of North America, 2012
- Quality of Life with Advanced Metastatic Prostate CancerUrologic Clinics of North America, 2012
- Concepts and definitions for “supportive care,” “best supportive care,” “palliative care,” and “hospice care” in the published literature, dictionaries, and textbooksSupportive Care in Cancer, 2012
- The EORTC quality of life questionnaire QLO-C30 (version 3.0): Validation study for spanish prostate cancer patientsArchivos Espanoles de Urologia, 2008
- Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancerQuality of Life Research, 2007
- Prostate cancer: palliative care and pain reliefProstate Cancer and Prostatic Diseases, 2004
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993